HALIFAX, Sept. 26, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a
developer of rapid diagnostic technology and solutions, announced today
that its largest and controlling shareholder, Andurja Beteiligungen AG
has changed its name to OnSite Lab Holding AG (OnSite Lab). OnSite Lab
has further partnered with a Luxembourg-based investment fund,
Redalpine Capital II S.C.S., SICAR (Redalpine Capital), and a private
investment company, RLG APS, located in Copenhagen to enhance its Board
and investment focus in life science companies.
"The substantial investment we have made in MedMira represents our
strong commitment, our focus, and a key element of our strategic plan.
By changing our company's name to OnSite Lab Holding AG, we are moving
a step closer to building an even stronger affiliation with MedMira. We
are bringing the expertise of Redalpine and RLG APS on to our Board to
provide additional industry capabilities to MedMira. Dr. Michael
Sidler, partner at Redalpine Capital, has a wealth of experience in the
life sciences and diagnostics industry and in linking science and
business entities. RLG APS is led by Dr. H.P. Richard, a well
established Swiss medical doctor will offer further assistance to
MedMira for its expansion into new business opportunities and financing
networks. We are committed to work with the Company's management and
its Board to deliver the best value to all stakeholders of MedMira,"
said Urs Meile, Chairman of OnSite Lab Holding AG.
Meile continued, "Our investment in MedMira is a chance to be a part of
an evolutionary shift in the rapid diagnostics market. We see MedMira
as an investment that not only covers the humanitarian side but it is
our strong belief that MedMira is one of the very few companies that
will yield a high return on investment in today's market."
"We are excited about the in-depth life sciences and diagnostics
industry knowledge, and business network brought by Dr. Sidler and Dr.
Richard through OnSite Lab. We believe that their expertise will be
invaluable in optimizing MedMira's strategic direction during the next
phase of our growth," said Hermes Chan, CEO, MedMira Inc.
Dr. Sidler has been nominated as the board representative for OnSite Lab
on MedMira's Board of Directors. This appointment is subject to final
approval of the TSX Venture Exchange.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics and technologies. The Company's tests provide hospitals,
labs, clinics and individuals with reliable, rapid diagnosis for
diseases such as HIV and hepatitis C in just three minutes. The
company's tests are sold under the Reveal®, Multiplo™ and Miriad brands
in global markets. MedMira's rapid flow-through HIV test is the only
one in the world to achieve regulatory approvals in Canada, the United
States, China and the European Union. MedMira's corporate offices and
manufacturing facilities are located in Halifax, Nova Scotia, Canada.
For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, including
statements relating to growth in the Company's business, earnings and
profitability, and trends in demand for the Company's products, which
involve risk and uncertainties and reflect the Company's current
expectation regarding future events including statements regarding
possible future growth and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process, establishment
of corporate alliances and other risks detailed from time to time in
the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MEDMIRA INC.
For further information:
Andrea Young, Corporate Communications